A Selection of Recent Papers

KRAS Mutation is Associated with Elevated Myeloblastin Activity in Human Lung Adenocarcinoma. T. WIEDL, S. COLLAUD, S. HILLINGER, S. ARNI, C. BURGESS, W. KROLL, P. SCHRAML, W. WEDE (Zurich, Switzerland; Cambridge, MA, USA)

Early detection of Ovarian Cancer in Pre-diagnosis Samples Using CA125 and MALDI MS Peaks. J.F. TIMMS et al (London; Reading, UK)

Decoding Differentially Regulated Epithelial and Stromal Pathways in Colorectal Cancer. M. ABBA, S. LAUFS, M. AGHAJANY, B. KORN, A. BENNER, H. ALLGAYER (Heidelberg, Germany)


Small Molecule Inhibition of Cytoskeletal Dynamics in Melanoma Tumors Results in Altered Transcriptional Expression Patterns of Key Genes Involved in Tumor Initiation and Progression. C. SPENCER, J. MONTALVO, B.A. BRYAN (Worcester, MA, USA)

Gene Expression Profile Can Predict Pathological Response to Preoperative Chemoradiotherapy in Rectal Cancer. M. NISHIOKA, M. SHIMADA, N. KURITA, T. IWATA, S. MORIMOTO, K. YOSHIIKAWA, H. HIGASHIUSA, T. MIYATANI (Tokushima, Japan)


Restoration of Senescence in Breast and Ovarian Cancer Cells Following the Transfer of the YAC Carrying SEN6A Gene Located at 6q16.3. N.S. RANE, A.K. SANDHU, V.S. ZHAWAR, G. KAUR, N.C. POPESCU, R.P. KANDPAL, M. JHANWAR-UNIYAL, R.S. ATIHAL (Philadelphia, PA; Bethesda, MD; Pomona, CA; Valhalla, NY, USA)

Therapy- , Gender- and Race- specific microRNA Markers, Target Genes and Networks Related to Glioblastoma Recurrence and Survival. K.R. DELFINO, N.V.L. SERAO, B.R. SOUTHEY, S.L. RODRIGUEZ-ZAS (Urbana, IL, USA)


The Cancer Biomarker Osteopontin: Combination with Other Markers (Review). G.F. WEBER (Cincinnati, OH, USA)

Epigenetic Inactivation of the Placentally Imprinted Tumor Suppressor Gene T.From2 in Prostate Carcinoma (Review). T. RIBARSKA, M. INGWER, W.A. ENGERS, N.V.L. SERAO, B.R. SOUTHEY, S.L. RODRIGUEZ-ZAS (Urbana, IL, USA)
Instructions to Authors

General Policy. IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research. The principal aim of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.

Manuscripts will be accepted on the understanding that they report original unpublished works that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to IN VIVO will be subject to review, when appropriate, by two members of the Editorial Board. The Editors reserve the right to improve manuscripts on grammar and style.

The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and at all times the animals must be treated humanely. The Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society must be followed.

The Editors and Publishers of IN VIVO accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in IN VIVO, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in IN VIVO, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “clinical”, ”epidemiological”, or ”experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author’s opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

Tables. Each table should be submitted on a separate page, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.


Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “NCT”). Please note that there is no space between the prefix “NCT” and the number. Example: NCT00001789.

Ethical Policies and Standards. CGP agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your articles twice.):
1. To submit your article online please visit: IIAR-Submissions (link to: http://www.iiar-anticancer.org/submissions/login.php)
2. You can send your article via e-mail to journals@iiar-anticancer.org (mail to: journals@iiar-anticancer.org). Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:
   John G. Delinassios, International Institute of Anticancer Research (IIAR), Editorial Office of ANTICANCER RESEARCH, IN VIVO and CANCER GENOMICS & PROTEOMICS, 1st km Kapandritiou-Kalamou Road, P.O. Box 22, GR-19014 Kapandriti, Attiki, GREECE.

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free-of-charge. Additional copies, PDF files, or/and Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2012 International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitter in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
Selection of Recent Articles


TGFB-α Regulation of Focal Adhesion Proteins and Motility of Premalignant Oral Lesions via Protein Phosphatase 1. J.E. WALSH, M.R. YOUNG (Charleston, SC, USA)

Angiogenesis Quantification in Breast Cancer by Automated Vessel Identification in CD34 Immunohistochemical Sections. L.T.G. MIKALSEN, H.P. DHAKAL, O.S. BRULAND, J.M. NESLAND, D.R. OLSEN (Oslo; Bergen, Norway)

Synergistic Activity of Histone Deacetylase and Proteasome Inhibition Against Pancreatic and Hepatocellular Cancer Cell Lines. J.L. SPRATLIN, T.M. PITTS, G.N. KULIKOWSKI, M.P. MORELLI, J.J. TENTLER, N.J. SERKOVÁ, S.G. ECKHARDT (Aurora, CO, USA; Edmonton, AB, Canada)

Synergistic Activity of Statin- and Cell Cycle Inhibitors for the Killing of Colon Cancer Cells. T. MURAI, T. TAKAMIYA, Y. KOBAYASHI, Y. ARIMA, T. KATAOKA, M. TAKAHASHI, K. OKADA, H. SUZUKI (Nagoya; Aichi, Japan)

Effect of Tamoxifen on the Expression of NODA, a Novel Apoptosis Inhibitor in Human Breast Cancer Cells. O. TSUKADA, S. YAMADA, R. NAGATA, M. KOBAYASHI, T. CHIKAZUMI, T. OKUI, T. KOBAYASHI, K. YAMANAKA, T. KAKIZAKI (Osaka; Kansai, Japan)

Synergistic Activity of Histone Deacetylase and Proteasome Inhibition Against Pancreatic and Hepatocellular Cancer Cell Lines. J.L. SPRATLIN, T.M. PITTS, G.N. KULIKOWSKI, M.P. MORELLI, J.J. TENTLER, N.J. SERKOVÁ, S.G. ECKHARDT (Aurora, CO, USA; Edmonton, AB, Canada)
Doxorubicin Induces Early Embryo Apoptosis by Inhibiting Poly(ADP ribose) Polymerase. Q.-L. WANG, S.-C. SUN, J. HAN, Y.-C. KWAK, N.-H. KIM and X.-S. CUI (Cheongju, South Korea) ........................................... 827

The Effects of Cetrorelix and Triptorelin on the Viability and Steroidogenesis of Cultured Human Granulosa Luteinized Cells. C. METALLINOU, F. KÖSTER, K. DIEDRICH, N. NIKOLETTOS and B. ASIMAKOPOULOS (Alexadroupolis, Greece; Lübeck, Germany) ......................................................................................... 835

Clinical Studies

Treatment of Sleep Apnoea Using a Mandibular Advancement Splint – An Open Prospective Study. A.-K. LEKERUD, L. SAND, A.-K. ENGLUND and J.M. HIRSCH (Uppsala, Sweden) ................................................................. 841


Obesity Effects on Cyclophosphamide-induced DNA Damage in Hematopoietic Cell Transplant Recipients. L. A. JOHNSON, N. TRETYAKOVA and P. A. JACOBSON (Minneapolis, MN, USA) ................................................................. 853

An Easy Method to Quantify Plasma Cells in Caeliac Disease. C.A. RUBIO, D. BUHRKHUL, M. PERDIKI and M. IDESTRÖM (Stockholm, Sweden) .................................................................................................................... 859

Comparing Bioelectrical Impedance Values in Assessing Early Upper Limb Lymphedema after Breast Cancer Surgery. S. BERLIT, J. BRADE, B. TUSCHY, A. HORSEMANN, H. LEWELING, V. EGHARDT and M. SÜTTERLIN (Mannheim, Germany) ................................................................................................. 863


* Reviews (pages 777, 799)